Abstract | The prokaryotic type II CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-CRISPR-associated 9) system is rapidly revolutionizing the field of genetic engineering, allowing researchers to alter the genomes of a large range of organisms with relative ease. Experimental approaches based on this versatile technology have the potential to transform the field of cancer genetics. Here, we review current approaches for functional studies of cancer genes that are based on CRISPR-Cas, with emphasis on their applicability for the development of next-generation models of human cancer.
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. Therefore, experimental approaches to manipulate the genomes of normal cells and cancer cells are vital for modelling the disease as well as systematically studying the many genes involved in the process. Decades of research and the development of genome-engineering technologies have made it possible to precisely delete, or other wise modify, specific DNA sequences in the genomes of cells in culture or of animal models to explore the role of genes implicated in cancer initiation, progression and therapeutic response. Pioneering work by Mario Capecchi, Oliver Smithies and others on gene targeting in embryonic stem (ES) cells via homologous recombination [2] [3] [4] provided the scientific community the means to generate numerous genetically engineered mouse models (GEMMs) harbouring precise mutations in tumour-suppressor genes and oncogenes, as well as cell lines with defined loss-of-function or gain-of-function alterations in genes that are relevant to cancer biology. Moreover, this technology has been successfully used in combination with site-specific recombinases, such as Cre and flippase (Flp), to generate conditional alleles of numerous cancer genes 5 . Although a mainstay of cancer genetics over the past two decades, these gene modification approaches have been limited by the relatively low efficiency of gene targeting by homologous recombination and by the time required for ES cell manipulation and subsequent mouse breeding.
One strategy to increase the efficiency of gene targeting is to introduce DNA doublestrand breaks (DSBs) at the genomic locus of interest [6] [7] [8] [9] [10] . These DSBs are repaired by cellular DNA repair pathways, particularly by the error-prone non-homologous end joining pathway (NHEJ pathway), which frequently leads to insertion or deletion mutations (indels). DSBs are also repaired by the homology-directed repair (HDR) pathway, which can mediate precise DNA modifications in the presence of exo genous donor DNA templates (FIG. 1a) . Subsequent studies based on these initial observations led to the development of improved genomeengineering methods using site-specific endonucleases, including zinc-finger nucleases (ZFNs) [10] [11] [12] and transcription activator-like effector nucleases (TALENs) [13] [14] [15] [16] , which have been used extensively in a range of cell types and organisms (reviewed in REFS 17, 18) . ZFNs and TALENs greatly facilitated precise genome engineering; however, their widespread adoption has been limited by the cost and complexity of designing these custom-built endonucleases.
The recently described prokaryotic CRISPR-Cas (clustered regularly interspaced short palindromic repeats-CRISPR-associated) system and the successful implementation of the Streptococcus pyogenes-derived type II CRISPR-Cas9 system in mammalian cells by the Zhang 19 , Church 20 , Doudna 21 and Kim 22 groups have rapidly changed the landscape of genome engineering by addressing many of the limitations of earlier methods. This highly versatile system, which is derived from a prokaryotic adaptive immune system, is composed of two biological components: the RNA-guided DNA endonuclease Cas9 and a chimeric single guide RNA (sgRNA). The sgRNA molecule contains both a CRISPR RNA (crRNA) component and a trans-activating crRNA (tracrRNA) component, which binds to Cas9 and directs it to a genomic sequence of interest via base pairing to the target sequence 23 (FIG. 1b) . The only criterion defining the target sequence is that it must be adjacent to a protospacer adjacent motif (PAM), which consists of either an NGG or an NAG trinucleotide 24 for S. pyogenes-derived Cas9 (of note, other Cas9 orthologues recognize different PAM sequences 25, 26 ). By simply combining the expression of Cas9 with an sgRNA that is complementary to a target DNA sequence, high-efficiency cleavage of the target can be achieved, leading to the formation of DSBs, which then get repaired via NHEJ or HDR (FIG. 1b) . Numerous studies published over just the past few years have demonstrated efficient gene disruption and gene modification in various cells and organisms via CRISPR-Cas9-mediated NHEJ and HDR, respectively (reviewed in REF. 27 ).
In this Progress article, we discuss several recent applications of the CRISPR-Cas9 system, with particular emphasis on approaches that promise to transform the field of cancer biology by facilitating the engineering of normal and cancer genomes.
Rapid modelling of genetic events
In the current era of cancer genomics, several large-scale cancer genome sequencing efforts have produced an expanding catalogue of the genetic alterations present in human tumours 28 . Among a background of so-called passenger mutations, which are presumed not to directly affect the tumorigenic process, driver mutations directly or indirectly Nature Reviews | Cancer Medium-scale to large-scale functional genetic studies aimed at dissecting the role of putative oncogenes and tumoursuppressor genes in cell culture, xenografts, allografts and, in some cases, transgenic mouse models have traditionally relied on cDNA-based overexpression and RNA interference (RNAi)-mediated knockdown approaches. Although these approaches have led to many recent important discoveries in cancer biology, they have several important limitations. cDNA-based expression systems can lead to supraphysiological levels of gene expression 29 , which might have aberrant and artefactual effects on signalling pathways and cell biological processes. RNAi-based inactivation approaches are limited by the uncertainty of the degree of gene silencing and the stability of the inhibition. This is not problematic for some targets or experimental protocols, but for others complete and permanent inactivation is required to obtain consistent results. RNAi-based approaches can also suffer from substantial off-target effects. The deployment of the CRISPR-Cas9 system for targeted modification of endogenous loci offers a rapid method for overcoming these limitations. In addition to simplifying the study of oncogenes and tumour-suppressor genes, the CRISPR-Cas9 system also allows for rapid discrimination between driver and passenger mutations.
Permanent Cas9-mediated modification of single or multiple endogenous loci can be achieved via transient or stable delivery of the CRISPR components. Several groups have reported successful editing of endo genous genes in cells in culture via transient transfection of plasmid DNA encoding Cas9 and sgRNAs [19] [20] [21] [22] or Cas9-sgRNA ribonucleoprotein complexes (RNPs) 30, 31 . Alternatively, CRISPR components can be stably delivered into cells through the use of retroviruses or lentiviruses 32, 33 . Engineering loss-of-function mutations relies on NHEJ, which often results in the generation of indels near the Cas9 cleavage site that frequently lead to frameshift mutations. Engineering gain-of-function mutations requires the inclusion of an HDR template in the form of single-stranded or double-stranded DNA carrying the desired mutation (FIGS 1b, 2) . Transient expression of the CRISPR components offers the advantage of a 'hit-and-run' strategy that should allow for unlimited serial editing of endogenous genes without the need for multiple viral integrations or continuous expression of CRISPR components. Cell lines carrying one or more targeted mutations can then be tested using a series of cell-based and in vivo assays to examine the effects of the mutation (or mutations) on cancer-associated phenotypes. This approach can be used on established cancer cell lines and primary cell lines of mouse or human origin, as well as on patient-derived xenografts and organoid cultures, among others (FIG. 2) . Moreover, this technology should allow for systematic analysis of epistatic interactions and comprehensive dissection of oncogenic signalling pathways via sequential or multiplex gene editing. In addition to allowing the functional characterization of true cancer genes, such studies can help to rule out a functional effect of a passenger mutation on cancer initiation and progression. Several review articles 27, 34 have recently described in detail most applications of the CRISPR-Cas9 system for genome engineering. We have summarized these applications in BOXES 1,2 and FIG. 2, and we focus below on the use of this technology for generating animal models for the study of cancer genes in vivo.
Rapid generation of mouse models GEMMs 5 and non-germline GEMMs (nGEMMs) 35 of cancer have played a critical part in uncovering several fundamental aspects of tumour initiation, maintenance and progression. In addition, they have emerged as faithful models with which to test a range of anticancer agents and to uncover mechanisms of drug resistance 36, 37 . However, generating GEMMs is a slow and expensive process, requiring complex ES cell manipulation and/or pronuclear injection, as well as extensive mouse husbandry to obtain animals harbouring the alleles of interest 35 . nGEMMs of cancer can simplify this process by bypassing the need for complex genetic crosses through the serial retargeting of ES cells 35 . Nevertheless, the inability to simultaneously introduce multiple genetic modifications in mice or ES cells remains a considerable barrier. pathway or the homology-directed repair (HDR) pathway. Repair via the NHEJ pathway, which is errorprone, frequently leads to insertion or deletion mutations (indels) that can lead to disruptive frameshift mutations and the generation of premature stop codons. Alternatively, in the presence of an exogenous donor DNA template, the DSB can be repaired via the HDR pathway, which can be used for engineering precise DNA modifications. b | The Streptococcus pyogenes-derived CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats--CRISPR-associated 9) RNA-guided DNA endonuclease is localized to a specific DNA sequence via a single guide RNA (sgRNA) sequence, which base-pairs with a specific target sequence that is adjacent to a protospacer adjacent motif (PAM) sequence in the form of NGG or NAG. Cas9-mediated induction of a DSB in the DNA target sequence leads to indel mutations via NHEJ or precise gene modification via HDR.
Jaenisch and colleagues 38 recently demonstrated that the CRISPR-Cas9 system can be used to simultaneously disrupt up to eight alleles in mouse ES cells in a single step. Furthermore, they reported efficient simultaneous disruption of two genes in single-cell mouse embryos and the subsequent one-step generation of doubleknockout animals 38 . This group also demonstrated efficient simultaneous HDR-mediated genome editing of two endogenous genes 38 . In a subsequent study, they extended their CRISPR-Cas9 methods for rapidly generating mice carrying conditional Cre-loxP-based alleles and reporter alleles, as well as using pairs of sgRNAs to generate mice carrying small deletions 39 (FIG. 2b,c) . These studies demonstrated the ease with which ES cells or mice harbouring multiple gain-of-function and loss-of-function mutations can be generated, an advance that has opened the door for the development of novel GEMMs and nGEMMs of cancer with unprecedented speed and precision. Indeed, we predict that there will be an explosion of novel GEMMs and nGEMMs harbouring uniquely complex genetic alterations that will allow for detailed analysis of several stages of tumour evolution with exceptional speed and efficiency (FIG. 3a) . For example, CRISPR-mediated engineering will allow for the rapid generation of large repositories of ES cell lines harbouring multiple combinations of constitutive or conditional mutations in oncogenes and tumour-suppressor genes, as well as large chromosomal rearrangements that will capture some of the genetic heterogeneity that is characteristic of human cancer genomes. These ES cell lines can be used to generate GEMMs and nGEMMs of cancer harbouring multiple distinct mutant genotypes, which will be highly valuable for testing new therapeutic regimens and for personalized oncology efforts.
It is important to note that most mouse cancer models have been based on a rather limited number of mutant genes or alleles, such as the G12D or G12V mutations in the Kras oncogene 40, 41 . The CRISPR-Cas9 system will allow for the systematic generation of models harbouring multiple oncogenic alleles, making it possible to investigate allele-specific consequences on tumour progression and therapeutic response. Highly systematic and multiplexable approaches for HDR-mediated editing of specific genomic regions, such as the methods developed by the Shendure laboratory 42 , will facilitate rapid analysis of 'hotspot' regions with various combinations of mutations and the subsequent generation of GEMMs and nGEMMs.
Glossary

Allografts
Tumour tissues or cell lines from one species that have been implanted into a recipient of the same species.
Cancer genes
Genes that have a causal role in carcinogenesis, such as tumour-promoting genes (commonly referred to as 'oncogenes') and tumour-suppressor genes.
Chimeric antigen receptor-modified T cells
(CAR T cells). T cells that have been modified to express a synthetically engineered T cell receptor composed of a single-chain antibody, that allows for tumour recognition, fused with additional intracellular signalling domains derived from the T cell receptor and other co-stimulatory molecules.
Conditional alleles
Engineered alleles, the expression of which is strictly dependent on the presence of a second component, such as Cre recombinase for loxP-based conditional alleles.
CRISPR RNA (crRNA). In natural CRISPR (clustered regularly interspaced short palindromic repeats) systems, CRISPR loci contain crRNAs that are composed of a repeat portion and a variable portion, the latter corresponding to invader-specific DNA sequences that form the basis of this prokaryotic adaptive immune system.
Genetically engineered mouse models (GEMMs). Mice genetically engineered to express either exogenous or endogenous mutated genes. For GEMMs of cancer, the modified genes are usually cancer genes. 
Hydrodynamic gene transfer
A technique that allows for delivery of DNA via the application of hydrodynamic pressure in capillaries, which greatly enhances endothelial and parenchymal cell permeability, leading to efficient transfer of DNA.
Indels
Mutations that arise because of small insertions or deletions of DNA sequences.
Non-homologous end joining pathway
(NHEJ pathway). An error-prone cellular DNA repair pathway that involves the modification and subsequent ligation of two broken DNA ends generated by a double-strand break. This pathway can result in insertion or deletion mutations due to the addition or removal of nucleotides at the break before ligation.
Organoid cultures
A type of in vitro culture in which stem cells or organ progenitors are embedded in a three-dimensional matrix in which they self-assemble into epithelia that very closely resemble the organ of origin. These organoid cultures offer several advantages over traditional cell culture, the main one being that they very closely recapitulate the physiology of the native epithelial organ of origin.
Patient-derived xenografts
A type of xenograft in which fresh tumour tissue obtained from a cancer patient is implanted directly into an immunodeficient mouse.
Protospacer adjacent motif (PAM). A nucleotide sequence immediately adjacent to the target sequence that is critically required for CRISPR (clustered regularly interspaced short palindromic repeats)-associated (Cas)-mediated recognition and cleavage. In natural CRISPR systems, the PAM sequence allows for self versus non-self discrimination by virtue of the absence of PAM sequences in endogenous CRISPR loci.
Single guide RNA (sgRNA). A chimeric RNA molecule generated by the fusion of a CRISPR (clustered regularly interspaced short palindromic repeats) RNA (crRNA) and a trans-activating crRNA (tracrRNA) that guides Cas9 (CRISPR-associated 9) to a specific genomic target via a unique guide RNA sequence present in the 5ʹ region of the crRNA.
Site-specific recombinases
Enzymes (for example, Cre and flippase (Flp)) that can catalyse the recombination between specific pairs of inverted repeat sequences (for example, loxP sequences for Cre and Flp recombination target (FRT) sequences for Flp).
Trans-activating crRNA (tracrRNA). In natural CRISPR (clustered regularly interspaced short palindromic repeats) systems, the tracrRNA is a trans-encoded RNA molecule that is critical for the processing of pre-CRISPR RNA (pre-crRNA) loci into mature crRNAs.
Transcription activator-like effector nucleases (TALENs). Site-specific DNA endonucleases that are composed of specific DNA-binding domains from TALE proteins and the nuclease domain of the FokI restriction enzyme.
Xenografts
Tumour tissues or cell lines from one species that have been implanted into another species. In cancer research, this frequently entails the implantation of material from one species into an ectopic or orthotopic site of an immunodeficient mouse. Beyond new model development, the CRISPR-Cas9 system can also be used to refine existing models of cancer. ES cell lines derived from well-studied GEMMs can be readily re-engineered to harbour additional constitutive or conditional mutant alleles of oncogenes and tumoursuppressor genes 43 (FIG. 3a) . Thus, candidate cooperating mutations can be easily studied, and putative synthetic lethal inter actions can be validated. Moreover, this approach will allow for preclinical studies consisting of cohorts of mice that better represent the genetic heterogeneity of human cancers (FIG. 3b) . One can even envision combining comprehensive genomic characterization of tumours from individual patients with the rapid generation of personalized GEMMs, nGEMMs or cell-based xenografts. In vivo models carrying the exact complement of driver mutations from a given patient's tumour could then be screened with conventional or experimental anticancer agents to identify the most effective therapies (FIG. 3c) .
Zinc-finger nucleases
Somatic genome engineering
As outlined above, the efficiency of genome editing by CRISPR-Cas9 makes the process of germline and ES cell line genetic manipulation more rapid and more powerful. The power of the system is even more evident in the ability to perform somatic genome editing ex vivo and in vivo. 45 used the CRISPR-Cas9 system to rapidly generate mouse models of AML by lentivirus-mediated ex vivo editing of single or multiple genes in primary mouse HSPCs. These three studies highlight the potential of the CRISPR-Cas9 system for ex vivo somatic genome editing of primary cells, which can be further exploited for the rapid generation of mouse models of various human malignancies (FIG. 3b) .
Ex vivo CRISPR-based somatic genome editing for modelling cancer in vivo.
In vivo CRISPR-based somatic genome editing for modelling cancer. To explore the use of the CRISPR-Cas9 system for directly mutating genes in living animals, our laboratory used hydrodynamic gene transfer to simultaneously deliver plasmids encoding Cas9 and sgRNAs targeting the Pten and Trp53 tumour-suppressor genes to hepatocytes in vivo 46 . Strikingly, delivery of these CRISPR plasmids to the hepatocytes of adult wild-type mice was sufficient to induce liver tumours with identical histopathology to those observed in Pten fl/fl Trp53 fl/fl GEMMs, in which tumours were initiated via delivery of adenoviruses expressing Cre recombinase. These results strongly suggest that CRISPR-mediated somatic genome editing of cancer genes in adult wild-type mice can efficiently substitute for traditional GEMMs, at least for some cancer types. Moreover, we further demonstrated the feasibility of using the CRISPR-Cas9 system to engineer gain-of-function mutations in the livers of adult wild-type mice via the co-delivery of CRISPR components and a single-stranded DNA template encoding a mutant form of β-catenin, which resulted in the generation of hepato cytes with nuclear β-catenin at a low (0.5%) but detectable frequency 46 . Moving beyond the liver, we also developed an all-in-one lentivirus simultaneously encoding CRISPR components and Cre recombinase. This vector was used to mutate three lung cancer tumour-suppressor genes in the developing tumours of the well-established GEMMs of lung cancer 40, 47, 48 . Intratracheal delivery of all-in-one lentiviruses expressing sgRNAs targeting a range of tumoursuppressor genes into Kras LSL−G12D/+ or Kras LSL−G12D/+ Trp53 fl/fl mice resulted in lung adenocarcinomas with diverse histopathological and molecular features that depended on the tumour-suppressor gene targeted. Moreover, a large fraction of the lung tumours harboured indels in predicted sites within the target genes with no detectable off-target editing, strongly supporting Cas9 on-target activity for somatic genome editing in vivo. In a parallel study, the Ventura group demonstrated the feasibility of using the CRISPR-Cas9 system for modelling large oncogenic chromosomal rearrangements (FIG. 2c) in wild-type mice in vivo via delivery of an adenovirus encoding Cas9 and two sgRNAs designed to induce an Eml4-Alk (echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase) inversion 49, 50 . Lung tumours developed with complete penetrance and 
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. Remarkably, the serial introduction of five independent mutations frequently associated with human CRC (three LOF mutations and two GOF mutations) did not fully recapitulate the tumorigenic and metastatic characteristics of the human disease, suggesting that additional secondary genetic and/or epigenetic events are required for full malignancy 77 . In addition, the ability to multiplex the CRISPR-Cas9 system offers the opportunity to investigate combinatorial vulnerabilities in cancer cells, as well as to systematically test epistatic relationships and synthetic lethal interactions (part a). This technology also allows for the generation of endogenous conditional alleles based on site-specific recombinases 39 , tagging of endogenous alleles 39 and interrogation of non-coding DNA elements
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(part b). The CRISPR-Cas9 system can also be used to trigger two distant double-strand breaks (DSBs) in the same or different chromosomes, leading to inversion, deletion or translocation of the target sequences (part c). This approach has been shown to be efficient in cells [79] [80] [81] [82] [83] [84] [85] [86] and in vivo 49, 52 . ALK, anaplastic lymphoma kinase; BCR, breakpoint cluster region; COSMIC, Catalogue of Somatic Mutations in Cancer; drug were exquisitely sensitive to crizotinib, an inhibitor used to treat human lung tumours that harbour this particular oncogenic rearrangement 51 . Moreover, the fact that the Eml4 and Alk loci are separated by ~11 megabases strongly supports the feasibility of the CRISPR-Cas9 system for modelling large genomic rearr angements. A subsequent study using lentiviruses also demonstrated the ability of the CRISPR-Cas9 system to induce chromosomal rearrangements in vivo 52 . These studies demonstrated the potential of rapidly generating mouse models of cancer via somatic genome engineering through delivery of all CRISPR components in the form of plasmids or viruses. In addition to these traditional DNA-based or virus-based delivery methods, recent advances in engineering of non-viral delivery materials have made it possible to deliver Cas9-sgRNA protein-RNA complexes 53 and sgRNA-nanoparticle complexes 54 in vivo using cationic lipidmediated delivery or 7C1 nanoparticles, respectively. Future advances in materials science and engineering should make it possible to implement additional types of nonviral delivery platforms for the delivery of Cas9, sgRNAs and HDR donor DNA templates for achieving highly efficient genome modification in vivo (non-viral materials are extensively reviewed in REF. 55 ).
To further streamline the generation of CRISPR-based somatic mouse models of cancer, the Zhang and Sharp laboratories 54 reported the generation of mouse models expressing constitutive or Cre-inducible versions of the Cas9 enzyme. By intratracheally delivering a novel adeno-associated virus (AAV) encoding six components -a Kras G12D HDR donor DNA template, sgRNAs targeting Kras, Stk11 (also known as Lkb1) and Trp53, Cre recombinase and Renilla reniformis luciferase -into mice expressing the Cre-inducible Cas9 allele, they were able to induce lung tumours in adult mice by simultaneously disrupting both tumour suppressors and engineering the oncogenic Kras G12D mutation. Recently, the Lowe laboratory reported the generation of a highly flexible mouse modelling platform consisting of transgenic mice co-expressing doxycycline-inducible alleles of Cas9 or the Cas9 D10A nickase variant 52 and constitutively expressed sgRNA cassettes 56 . Using this conditional platform, they demonstrated effective gene editing in vivo with up to 85% target gene modification. Moreover, they demonstrated efficient simultaneous biallelic modification of up to two genes in vivo using a pair of sgRNAs and the Cas9 nuclease. This flexible platform allowed them to accommodate up to six sgRNA cassettes that, when combined with the Cas9 D10A nickase, led to simultaneous editing of three genes in mouse ES cells with high efficiency.
The development of mouse models expressing the Cas9 nuclease and Cas9 D10A nickase represents a major advancement for CRISPR applications in cancer biology, allowing researchers to focus their efforts on delivering single or multiple sgRNAs with or without synthetic HDR donor DNA templates using viral and/or non-viral carriers, bypassing the need to optimize approaches for co-delivery of this large DNA endonuclease. In addition, expression of Cre-inducible or doxycyclineinducible alleles of Cas9 in vivo can be rendered tissue-specific via the incorporation of tissue-specific Cre or reverse tetracycline transactivator alleles, respectively. Moreover, the development of constitutive and conditional mouse models for CRISPR-mediated activation 57 or repression 58 of gene expression (BOX 1) will serve as powerful complementary approaches for functionally studying both coding and non-coding DNA elements without permanent disruption of the endogenous genomic sequence. Beyond the established
Box 1 | Potential applications of dCas9-effector fusions in cancer biology
The ability of CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-CRISPR-associated 9) to bind in a specific RNA-dependent fashion can be uncoupled from its nuclease activity by mutating its HNH and RuvC-like catalytic domains. This catalytically inactive form of Cas9, often referred to as dead Cas9 (dCas9), retains its RNA-guided DNA-binding activity without any detectable DNA endonuclease activity 23 . A series of studies demonstrated the power of dCas9-effector fusions for reversible transcriptional repression 58, 65, 66 (see the figure, part a) or activation 25, 57, 58, [65] [66] [67] [68] [69] [70] [71] (see the figure, part b) of endogenous coding and non-coding genes. In addition, scaffold RNAs that encode both targeting and effector-recruitment functions can be used for simultaneous multiplex gene repression and activation within a single cell (see the figure, part c) 72 .
sgRNA, single guide RNA.
We envision a new era in cancer biology in which CRISPRbased genome engineering will serve as an important conduit between the bench and the bedside Nature Reviews | Cancer Mus musculus laboratory organism, the flexibility of CRISPR-Cas9 technologies should allow for the rapid generation of novel animal models of cancer using genetically intractable organisms that better recapitulate human tissue architecture and drug metabolism, such as pigs 59 and non-human primates 60 .
Future applications to cancer biology
We envision a new era in cancer biology in which CRISPR-based genome engineering will serve as an important conduit between the bench and the bedside (FIG. 3c) . The successful deployment of sophisticated geneticprofiling technologies for comprehensive characterization of a patient's tumour is generating detailed roadmaps to instruct the development of tailored cell-based or whole animal-based experimental systems. These systems will serve as personalized platforms with which researchers will rapidly and systematically identify genotype-specific vulnerabilities and synthetic lethal interactions via single or multiplex CRISPR-based and small molecule-based approaches. Moreover, such personalized platforms could be studied in parallel to the patients, potentially allowing for the rapid identification of resistance mechanisms and the development of strategies to overcome such shortcomings 61 . Although there are current technical limitations to the use of CRISPR-Cas9 for targeting cancer genes in human patients as a therapeutic strategy, the prospects of this form of gene therapy are nonetheless very exciting. Recent work has demonstrated the potential of this technology to permanently correct genetic mutations in vivo in the adult liver of mouse models of a hereditary genetic disease via HDR, successfully alleviating aspects of the disorder 62 . Therefore, future advancements of this technology for increasing the efficiency of editing and delivery of CRISPR-Cas9 components using both viral and non-viral delivery vehicles will allow for therapeutic genetic correction of single or multiple driver mutations. In addition to permanently correcting cancerassociated mutations, the CRISPR-Cas9 system could be used for precise ex vivo engineering of immune cells for immunotherapeutic applications. For example, the Box 2 | High-throughput genetic screens using CRISPR-Cas9
The flexibility of CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-CRISPR-associated 9) technology has recently been exploited for carrying out high-throughput CRISPR screens using the Cas9 nuclease 33, [73] [74] [75] [76] and dead Cas9 (dCas9)-effectors 66, 71 for the systematic identification of genes involved in various biological phenotypes (see the figure) . The Sabatini and Lander groups 73 designed and used a library of ~73,000 single guide RNAs (sgRNAs) targeting human genes to screen for genes involved in the DNA-mismatch repair pathway (MMR) in the presence of the nucleotide analogue 6-thioguanine (6-TG) and for genes whose disruption conferred resistance to the topoisomerase 2α (TOP2A) poison etoposide. Strikingly, both CRISPR screens demonstrated a very high signal-to-noise ratio, with the top scoring sgRNAs from each screen targeting genes involved in the MMR pathway and TOP2A itself, respectively. In a parallel study, Zhang and colleagues 33 generated and screened a library of ~65,000 sgRNAs targeting human genes and successfully identified essential genes in both cancer cell lines and pluripotent stem cells. Moreover, they used this library for performing a positive selection screen in melanoma cell lines to uncover genes, the deletion of which mediates resistance to the BRAF-V600E inhibitor vemurafenib, successfully identifying several known and novel candidates mediating resistance to this targeted therapy. Additional contemporaneous studies by Koike-Yusa et al. 74 and Zhou et al. 75 successfully demonstrated the broad applicability of pooled CRISPR-based screening technologies for identifying host factors mediating toxin susceptibility in mouse embryonic stem cells and human cells, respectively. In addition to CRISPR-based screens utilizing the Cas9 nuclease, the Weissman group 66 adapted dCas9-based activators and repressors to carry out powerful complementary genome-wide gene activation and repression screens, respectively. A subsequent study by Zhang's laboratory 71 also demonstrated the successful adaptation of dCas9-based activators for genome-wide gene activation screens. Notably, Zhang's group also demonstrated the feasibility of identifying mediators of vemurafenib resistance. These landmark studies demonstrated the feasibility of carrying out pooled high-throughput screens using CRISPR-Cas9 technologies to uncover genes mediating numerous biological phenotypes, as well as cancer cell vulnerabilities and mechanisms of therapeutic response and resistance. In addition to in vitro screens, the Zhang and Sharp laboratories 76 recently demonstrated the utility of the CRISPR-Cas9 system for performing genome-wide in vivo screens to uncover genes involved in tumour progression and metastasis. These alterations include constitutive or conditional knockout and knock-in alleles, endogenous synthetic tags or reporters, non-coding single-nucleotide polymorphisms (SNPs) and genomic rearrangements, as well as a combination of all of these via re-engineering of ES cells or multiplex CRISPR-mediated genome engineering. b | CRISPR-mediated somatic genome engineering in vivo can be used to rapidly generate cohorts of tumour-bearing mice for studying both basic and translational aspects of cancer biology. For example, the CRISPR-Cas9 (CRISPR-associated 9) system can be deployed in vivo for generating cohorts of personalized mice based on the exact complement of mutations observed in individual patients. c | The CRISPR-Cas9 system can serve as an important conduit between the bench and the bedside. The combination of sophisticated molecular profiling technologies with CRISPR-based genome engineering technologies will allow researchers to generate personalized experimental platforms that can be utilized for rapidly and systematically identifying novel genotype-specific vulnerabilities through a series of cell-based and in vivo assays. AAVs, adenoassociated viruses; Flp, flippase; FRT, Flp recombination target; HDR, homology-directed repair; PDX, patient-derived xenograft.
CRISPR-Cas9 system could be exploited for the development of novel chimeric antigen receptor-modified T cells (CAR T cells) 63 , in which the CAR is precisely inserted into a safe harbour locus 64 .
Since the Doudna and Charpentier groups 23 demonstrated the potential of the CRISPR-Cas9 system as a powerful RNA-programmed genome-editing platform, the field of genome engineering has rapidly undergone a scientific revolution that promises to transform nearly every aspect of basic biological and biomedical research. The application of this technology to several aspects of cancer biology, ranging from basic research to clinical and translational applications, offers numerous exciting opportunities for better understanding and potentially treating this devastating disease.
